repaglinide has been researched along with Cognition Disorders in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Areosa Sastre, A; González-Colaço Harmand, M; Martínez, G; Vernooij, RW | 1 |
| Burgos, DF; Dopazo, XM; González, P; González, V; López-Hurtado, A; Mellström, B; Naranjo, JR; Rábano, A | 1 |
| Morley, JE | 1 |
2 review(s) available for repaglinide and Cognition Disorders
| Article | Year |
|---|---|
Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia.
Topics: Carbamates; Cause of Death; Cognition Disorders; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic Agents; Memory Disorders; Metformin; Piperidines; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2017 |
The elderly Type 2 diabetic patient: special considerations.
Topics: Aged; Amyloid; Blood Glucose; Carbamates; Cognition Disorders; Depression; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Islet Amyloid Polypeptide; Male; Piperidines | 1998 |
1 other study(ies) available for repaglinide and Cognition Disorders
| Article | Year |
|---|---|
Inhibition of DREAM-ATF6 interaction delays onset of cognition deficit in a mouse model of Huntington's disease.
Topics: Activating Transcription Factor 6; Animals; Carbamates; Cognition Disorders; Disease Models, Animal; Hippocampus; Humans; Huntington Disease; Kv Channel-Interacting Proteins; Memory Disorders; Mice, Inbred C57BL; Mice, Transgenic; Neuronal Calcium-Sensor Proteins; Neurons; Piperidines; Rotarod Performance Test | 2018 |